Patient characteristics (n = 30)
| . | No. of patients/No. of evaluable patients . | Mean . | Range . |
|---|---|---|---|
| Age, y | |||
| <10 | 13 | 14 | 0.5-45 |
| 10-20 | 11 | ||
| 21-40 | 4 | ||
| >40 | 2 | ||
| Body weight, kg | 39 | 5-83 | |
| Karnofsky index, % | 65 | 20-100 | |
| Diagnosis | |||
| Acute lymphoblastic leukemia | 14 | ||
| Acute myeloid leukemia | 4 | ||
| Chronic myeloid leukemia | 1 | ||
| Myelodysplastic syndrome | 1 | ||
| Solid tumor | 1 | ||
| Immunodeficiency | 7 | ||
| Congenital bone marrow failure | 1 | ||
| Non-Hodgkin lymphoma | 1 | ||
| Graft | |||
| Matched unrelated donor | 7 | ||
| Matched sibling donor | 3 | ||
| Mismatched unrelated donor (<9/10 matched) | 3 | ||
| Haploidentical HSCT from parents or siblings | 17 | ||
| T-cell depletion | |||
| In vivo depletion (ATG) | 7 | ||
| Graft manipulation (plus serotherapy) | 17 | ||
| Alemtuzumab | 4 | ||
| Antiviral drugs for treatment of AdV | |||
| Cidofovir | |||
| Before ACT | 28/29 | ||
| After ACT | 20/27 | ||
| Ribavirin | 19/26 | ||
| Time of first positive AdV PCR in days after HSCT | |||
| In stool (n = 30) | 29 | –80-275 | |
| In blood (n = 28) | 36 | –71-305 | |
| Days to ACT after HSCT (± SD)] | 56 ± 61 | ||
| <50 | 25 | ||
| 50-100 | 7 | ||
| >100 | 6 |
| . | No. of patients/No. of evaluable patients . | Mean . | Range . |
|---|---|---|---|
| Age, y | |||
| <10 | 13 | 14 | 0.5-45 |
| 10-20 | 11 | ||
| 21-40 | 4 | ||
| >40 | 2 | ||
| Body weight, kg | 39 | 5-83 | |
| Karnofsky index, % | 65 | 20-100 | |
| Diagnosis | |||
| Acute lymphoblastic leukemia | 14 | ||
| Acute myeloid leukemia | 4 | ||
| Chronic myeloid leukemia | 1 | ||
| Myelodysplastic syndrome | 1 | ||
| Solid tumor | 1 | ||
| Immunodeficiency | 7 | ||
| Congenital bone marrow failure | 1 | ||
| Non-Hodgkin lymphoma | 1 | ||
| Graft | |||
| Matched unrelated donor | 7 | ||
| Matched sibling donor | 3 | ||
| Mismatched unrelated donor (<9/10 matched) | 3 | ||
| Haploidentical HSCT from parents or siblings | 17 | ||
| T-cell depletion | |||
| In vivo depletion (ATG) | 7 | ||
| Graft manipulation (plus serotherapy) | 17 | ||
| Alemtuzumab | 4 | ||
| Antiviral drugs for treatment of AdV | |||
| Cidofovir | |||
| Before ACT | 28/29 | ||
| After ACT | 20/27 | ||
| Ribavirin | 19/26 | ||
| Time of first positive AdV PCR in days after HSCT | |||
| In stool (n = 30) | 29 | –80-275 | |
| In blood (n = 28) | 36 | –71-305 | |
| Days to ACT after HSCT (± SD)] | 56 ± 61 | ||
| <50 | 25 | ||
| 50-100 | 7 | ||
| >100 | 6 |